Form 4: Apogee Therapeutics CEO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson sold 19,000 shares of common stock on June 10, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, Chief Executive Officer and a Director of Apogee Therapeutics, Inc. (APGE), reported the sale of common stock.
• A total of 19,000 shares of common stock were disposed of on June 10, 2026.
• The sales were executed in multiple transactions at weighted average prices ranging from $82.21 to $86.89 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on August 13, 2025.
• Following these transactions, Michael Henderson's direct beneficial ownership of common stock decreased from 1,114,987 shares to 1,095,987 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-arranged 10b5-1 plan, which typically minimizes the signaling effect of insider transactions, as it is not a discretionary sale based on new information.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales executed under a pre-arranged Rule 10b5-1 trading plan are generally considered routine and less indicative of management's immediate sentiment about the company's prospects compared to unscheduled sales. Such plans are often established for personal financial planning purposes, such as diversification or liquidity, and are set up when the insider is not in possession of material non-public information.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its execution under a 10b5-1 plan suggests it is part of routine financial planning and not a signal of negative company outlook.

Key Dates

Recommendation

The insider sale by the CEO, while reducing his direct ownership, was conducted under a pre-established 10b5-1 trading plan. Such planned sales are generally not considered a strong indicator of future stock performance or a change in management's confidence. Therefore, the filing itself does not provide a basis for a 'buy' or 'sell' recommendation, leading to a 'hold' stance based solely on this information.

Keywords

Apogee Therapeutics, APGE, Insider Sale, Form 4, Michael Henderson, CEO, Stock Sale, 10b5-1 Plan